强生艾伯维的CNS分歧

生物制药小编
19 Jan

又一家药企在精神分裂症治疗领域栽了跟头。1月16日,勃林格殷格翰公布了iclepertin治疗成人精神分裂症认知障碍的3期临床项目CONNEX的主要结果,该项目的主要终点和关键次要终点均未达到预期。基于此,勃林格殷格翰决定立即终止长期拓展试验CONNEX-X。这是近期在精神分裂症领域折戟的第二家巨头药企。此前不久,艾伯维收购Cerevel所得的“王牌项目”emraclidine,在两项针对...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10